293 related articles for article (PubMed ID: 31571826)
1. Preclinical pharmacodynamic and pharmacokinetic characterization of the major metabolites of cariprazine.
Kiss B; Némethy Z; Fazekas K; Kurkó D; Gyertyán I; Sághy K; Laszlovszky I; Farkas B; Kirschner N; Bolf-Terjéki E; Balázs O; Lendvai B
Drug Des Devel Ther; 2019; 13():3229-3248. PubMed ID: 31571826
[TBL] [Abstract][Full Text] [Related]
2. Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile.
Kiss B; Horváth A; Némethy Z; Schmidt E; Laszlovszky I; Bugovics G; Fazekas K; Hornok K; Orosz S; Gyertyán I; Agai-Csongor E; Domány G; Tihanyi K; Adham N; Szombathelyi Z
J Pharmacol Exp Ther; 2010 Apr; 333(1):328-40. PubMed ID: 20093397
[TBL] [Abstract][Full Text] [Related]
3. Population Pharmacokinetics of Cariprazine and its Major Metabolites.
Periclou A; Phillips L; Ghahramani P; Kapás M; Carrothers T; Khariton T
Eur J Drug Metab Pharmacokinet; 2021 Jan; 46(1):53-69. PubMed ID: 33141308
[TBL] [Abstract][Full Text] [Related]
4. Mini Review on Cariprazine: A Promising Antipsychotic Agent.
Patel A; Patel A; Patel D; Patel K; Bambharoliya T
CNS Neurol Disord Drug Targets; 2023; 22(2):226-236. PubMed ID: 35331126
[TBL] [Abstract][Full Text] [Related]
5. The Role of Dopamine D
Huang M; He W; Kiss B; Farkas B; Adham N; Meltzer HY
J Pharmacol Exp Ther; 2019 Nov; 371(2):517-525. PubMed ID: 31511365
[TBL] [Abstract][Full Text] [Related]
6. Cariprazine for the Treatment of Schizophrenia: A Review of this Dopamine D3-Preferring D3/D2 Receptor Partial Agonist.
Citrome L
Clin Schizophr Relat Psychoses; 2016; 10(2):109-19. PubMed ID: 27440212
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics, Safety, and Tolerability of Cariprazine in Pediatric Patients with Bipolar I Disorder or Schizophrenia.
Riccobene T; Riesenberg R; Yeung PP; Earley WR; Hankinson AL
J Child Adolesc Psychopharmacol; 2022 Oct; 32(8):434-443. PubMed ID: 36282772
[No Abstract] [Full Text] [Related]
8. In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist.
Glennon JC; Van Scharrenburg G; Ronken E; Hesselink MB; Reinders JH; Van Der Neut M; Long SK; Feenstra RW; McCreary AC
Synapse; 2006 Dec; 60(8):599-608. PubMed ID: 17001660
[TBL] [Abstract][Full Text] [Related]
9. Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [(11)C]-(+)-PHNO.
Girgis RR; Slifstein M; D'Souza D; Lee Y; Periclou A; Ghahramani P; Laszlovszky I; Durgam S; Adham N; Nabulsi N; Huang Y; Carson RE; Kiss B; Kapás M; Abi-Dargham A; Rakhit A
Psychopharmacology (Berl); 2016 Oct; 233(19-20):3503-12. PubMed ID: 27525990
[TBL] [Abstract][Full Text] [Related]
10. F15063, a potential antipsychotic with dopamine D2/D3 receptor antagonist, 5-HT1A receptor agonist and dopamine D4 receptor partial agonist properties: influence on neuronal firing and neurotransmitter release.
Assié MB; Mnie-Filali O; Ravailhe V; Benas C; Marien M; Bétry C; Zimmer L; Haddjeri N; Newman-Tancredi A
Eur J Pharmacol; 2009 Apr; 607(1-3):74-83. PubMed ID: 19326477
[TBL] [Abstract][Full Text] [Related]
11. Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents.
Gyertyán I; Kiss B; Sághy K; Laszy J; Szabó G; Szabados T; Gémesi LI; Pásztor G; Zájer-Balázs M; Kapás M; Csongor EÁ; Domány G; Tihanyi K; Szombathelyi Z
Neurochem Int; 2011 Nov; 59(6):925-35. PubMed ID: 21767587
[TBL] [Abstract][Full Text] [Related]
12. The role of dopamine D
Calabrese F; Tarazi FI; Racagni G; Riva MA
CNS Spectr; 2020 Jun; 25(3):343-351. PubMed ID: 31010452
[TBL] [Abstract][Full Text] [Related]
13. Comparative effect of lurasidone and blonanserin on cortical glutamate, dopamine, and acetylcholine efflux: role of relative serotonin (5-HT)2A and DA D2 antagonism and 5-HT1A partial agonism.
Huang M; Panos JJ; Kwon S; Oyamada Y; Rajagopal L; Meltzer HY
J Neurochem; 2014 Mar; 128(6):938-49. PubMed ID: 24164459
[TBL] [Abstract][Full Text] [Related]
14. Blonanserin extensively occupies rat dopamine D3 receptors at antipsychotic dose range.
Baba S; Enomoto T; Horisawa T; Hashimoto T; Ono M
J Pharmacol Sci; 2015 Mar; 127(3):326-31. PubMed ID: 25837930
[TBL] [Abstract][Full Text] [Related]
15. Cariprazine in Pediatric Patients with Autism Spectrum Disorder: Results of a Pharmacokinetic, Safety and Tolerability Study.
Yeung PP; Johnson KA; Riesenberg R; Orejudos A; Riccobene T; Kalluri HV; Malik PR; Varughese S; Findling RL
J Child Adolesc Psychopharmacol; 2023 Aug; 33(6):232-242. PubMed ID: 37437109
[No Abstract] [Full Text] [Related]
16. WS-50030 [7-{4-[3-(1H-inden-3-yl)propyl]piperazin-1-yl}-1,3-benzoxazol-2(3H)-one]: a novel dopamine D2 receptor partial agonist/serotonin reuptake inhibitor with preclinical antipsychotic-like and antidepressant-like activity.
Brennan JA; Graf R; Grauer SM; Navarra RL; Pulicicchio CM; Hughes ZA; Lin Q; Wantuch C; Rosenzweig-Lipson S; Pruthi F; Lai M; Smith D; Goutier W; van de Neut M; Robichaud AJ; Rotella D; Feenstra RW; Kruse C; Broqua P; Beyer CE; McCreary AC; Pausch MH; Marquis KL
J Pharmacol Exp Ther; 2010 Jan; 332(1):190-201. PubMed ID: 19828876
[TBL] [Abstract][Full Text] [Related]
17. Occupancy of dopamine D₂ and D₃ and serotonin 5-HT₁A receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomography.
Seneca N; Finnema SJ; Laszlovszky I; Kiss B; Horváth A; Pásztor G; Kapás M; Gyertyán I; Farkas S; Innis RB; Halldin C; Gulyás B
Psychopharmacology (Berl); 2011 Dec; 218(3):579-87. PubMed ID: 21625907
[TBL] [Abstract][Full Text] [Related]
18. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator.
Maeda K; Sugino H; Akazawa H; Amada N; Shimada J; Futamura T; Yamashita H; Ito N; McQuade RD; Mørk A; Pehrson AL; Hentzer M; Nielsen V; Bundgaard C; Arnt J; Stensbøl TB; Kikuchi T
J Pharmacol Exp Ther; 2014 Sep; 350(3):589-604. PubMed ID: 24947465
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of action of cariprazine.
Stahl SM
CNS Spectr; 2016 Apr; 21(2):123-7. PubMed ID: 26956157
[TBL] [Abstract][Full Text] [Related]
20. S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol.
Millan MJ; Gobert A; Newman-Tancredi A; Audinot V; Lejeune F; Rivet JM; Cussac D; Nicolas JP; Muller O; Lavielle G
J Pharmacol Exp Ther; 1998 Sep; 286(3):1341-55. PubMed ID: 9732398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]